Lenz & Staehelin represented Samsung Bioepis – part of the Samsung Bioepis group, the developer of the biosimilar Pyzchiva – in a patent nullity proceedings before the Swiss Federal Patent Court. On 12 August 2025, the Court upheld a
Lenz & Staehelin represented Samsung Bioepis – part of the Samsung Bioepis group, the developer of the biosimilar Pyzchiva – in a patent nullity proceedings before the Swiss Federal Patent Court. On 12 August 2025, the Court upheld a